Primary care screening and treatment for latent tuberculosis infection in adults: Evidence report and systematic review for the US Preventive Services Task Force

JAMA - Journal of the American Medical Association

Volumn 316, Issue 9, 2016, Pages 970-983

  Kahwati, Leila C ^a,b   Feltner, Cynthia ^a,c   Halpern, Michael ^a,b   Woodell, Carol L ^a,b   Boland, Erin ^a   Amick, Halle R ^a   Weber, Rachel Palmieri ^a   Jonas, Daniel E ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b RTI INTERNATIONAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PLACEBO; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC THERAPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; INFECTION PREVENTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; META ANALYSIS; MORTALITY; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUBERCULIN TEST; TUBERCULOSIS CONTROL; UNITED STATES; PRIMARY HEALTH CARE; REPRODUCIBILITY; STANDARDS;

ADULT; ANTITUBERCULAR AGENTS; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; PRIMARY HEALTH CARE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST;

EID: 84995772592     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.10357     Document Type: Review

References (106)

1. Advisory Council for the Elimination of Tuberculosis (ACET). Tuberculosis elimination revisited: Obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep. 1999; 48(RR-9): 1-13.
2. Geiter L, ed. Ending Neglect: The Elimination of Tuberculosis in the United States.Washington, DC: National Academy Press; 2000.
3. Miramontes R, Hill AN, YelkWoodruff RS, et al. Tuberculosis infection in the United States: Prevalence estimates from the National Health and Nutrition Examination Survey, 2011-2012. PLoS One. 2015; 10(11): E0140881.
4. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004; 350(20): 2060-2067.
5. Taylor Z, Nolan CM, Blumberg HM; American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. Controlling tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2005; 54(RR-12): 1-81.
6. World Health Organization. Guidelines on the Management of Latent Tuberculosis Infection. Geneva, Switzerland: World Health Organization; 2015.
7. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000; 49(RR-6): 1-51.
8. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep. 2010; 59(RR-5): 1-25.
9. World Health Organization. Tuberculosis Country Profiles. http://www.who.int/tb/country/data/profiles/en/. November 5, 2014. Accessed May 21, 2015.
10. United Nations Development Programme. UNDP Human Development Report 2014: Sustaining Human Progress: Reducing Vulnerabilities and Building Resilience. http://hdr .undp.org/sites/default/files/hdr14-report-en-1.pdf. 2014. Accessed March 30, 2016.
11. Harris RP, Helfand M,Woolf SH, et al; Methods Work Group, Third US Preventive Services Task Force. Current methods of the US Preventive Services Task Force: A review of the process. Am J Prev Med. 2001; 20(3)(suppl): 21-35.
12. West SL, Gartlehner G, Mansfield AJ, et al. Comparative Effectiveness ReviewMethods: Clinical Heterogeneity. Rockville, MD: Agency for Healthcare Research and Quality; 2010. AHRQ Publication 10-EHC070-EF.
13. Nyaga VN, Arbyn M, Aerts M. Metaprop: A Stata command to perform meta-Analysis of binomial data. Arch Public Health. 2014; 72(1): 39.
14. StataCorp. Stata Statistical Software Release 13.1. College Station, TX: StataCorp LP; 2013.
15. Falk A, Fuchs GF. Prophylaxis with isoniazid in inactive tuberculosis: A Veterans Administration Cooperative Study XII. Chest. 1978; 73(1): 44-48.
16. Bush OB Jr, Sugimoto M, Fujii Y, Brown FA Jr. Isoniazid prophylaxis in contacts of persons with known tuberculosis: Second report. Am Rev Respir Dis. 1965; 92(5): 732-740.
17. Veening GJ. Long term isoniazid prophylaxis: Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. Bull Int Union Tuberc. 1968; 41: 169-171.
18. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis. 1963; 88: 161-175.
19. BaileyWC,Weill H, DeRouen TA, Ziskind MM, Jackson HA. The effect of isoniazid on transaminase levels. Ann Intern Med. 1974; 81(2): 200-202.
20. Byrd RB, Horn BR, Griggs GA, Solomon DA. Isoniazid chemoprophylaxis: Association with detection and incidence of liver toxicity. Arch Intern Med. 1977; 137(9): 1130-1133.
21. Kontopantelis E, Reeves D. metaan: Random-effects meta-Analysis. Stata J. 2010; 10(3): 395-407.
22. Kontopantelis E, Springate DA, Reeves D. A re-Analysis of the Cochrane Library data: The dangers of unobserved heterogeneity in meta-Analyses. PLoS One. 2013; 8(7): E69930.
23. Hardy RJ, Thompson SG. A likelihood approach to meta-Analysis with random effects. Stat Med. 1996; 15(6): 619-629.
24. Jackson D, White IR, Thompson SG. Extending DerSimonian and Laird'smethodology to perform multivariate random effects meta-Analyses. Stat Med. 2010; 29(12): 1282-1297.
25. Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-Analysis of inconsistent effects: A time for change. Ann Intern Med. 2014; 160(4): 267-270.
26. Painter JA, Graviss EA, Hai HH, et al. Tuberculosis screening by tuberculosis skin test or QuantiFERON-TB Gold In-Tube assay among an immigrant population with a high prevalence of tuberculosis and BCG vaccination. PLoS One. 2013; 8(12): E82727.
27. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-SadrW. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol. 2006; 44 (8): 2844-2850.
28. Adetifa IM, Lugos MD, Hammond A, et al. Comparison of two interferon gamma release assays in the diagnosis of Mycobacterium tuberculosis infection and disease in The Gambia. BMC Infect Dis. 2007; 7: 122.
29. Pai M, Joshi R, BandyopadhyayM, et al. Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-Tuberculosis treatment. Infection. 2007; 35(2): 98-103.
30. Legesse M, Ameni G, Mamo G, Medhin G, Bjune G, Abebe F. Performance of QuantiFERON-TB Gold In-Tube (QFTGIT) for the diagnosis of Mycobacterium tuberculosis (Mtb) infection in Afar Pastoralists, Ethiopia. BMC Infect Dis. 2010; 10: 354.
31. Tan CK, Lai CC, Chen HW, et al. Enzyme-linked immunospot assay for interferon-gamma to support the diagnosis of tuberculosis in diabetic patients. Scand J Infect Dis. 2010; 42(10): 752-756.
32. Qian F,WangW, Qiu Z, et al. Evaluation of a new tuberculosis-related interferon gamma release assay for tuberculosis infection diagnosis in Huzhou, eastern China. Indian J Pathol Microbiol. 2013; 56(2): 125-128.
33. Wang S, Chen J, Zhang Y, et al. Mycobacterium tuberculosis region of difference (RD) 2 antigen Rv1985c and RD11 antigen Rv3425 have the promising potential to distinguish patients with active tuberculosis from M. bovis BCG-vaccinated individuals. Clin Vaccine Immunol. 2013; 20(1): 69-76.
34. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005; 293(22): 2756-2761.
35. Chee CB, Gan SH, Khinmar KW, et al. Comparison of sensitivities of two commercial gamma interferon release assays for pulmonary tuberculosis. J Clin Microbiol. 2008; 46(6): 1935-1940.
36. Harada N, Higuchi K, Yoshiyama T, et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect. 2008; 56(5): 348-353.
37. Kobashi Y, Mouri K, Yagi S, et al. Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis. Intern Med. 2008; 47(4): 237-243.
38. Kobashi Y, Mouri K, Yagi S, et al. Clinical evaluation for diagnosing active TB disease and transitional change of two commercial blood tests. Scand J Infect Dis. 2008; 40(8): 629-634.
39. Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest. 2008; 133(5): 1196-1202.
40. Soysal A, Torun T, Efe S, Gencer H, Tahaoglu K, Bakir M. Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection. Int J Tuberc Lung Dis. 2008; 12(1): 50-56.
41. Ak O, Dabak G, Ozer S, Saygi A, Dabak R. The evaluation of the Quantiferon-TB Gold test in pulmonary and extrapulmonary tuberculosis. Jpn J Infect Dis. 2009; 62(2): 149-151.
42. Higuchi K, Kawabe Y, Mitarai S, Yoshiyama T, Harada N, Mori T. Comparison of performance in two diagnostic methods for tuberculosis infection. Med Microbiol Immunol. 2009; 198(1): 33-37.
43. Kobashi Y, Sugiu T, Shimizu H, et al. Clinical evaluation of the T-SPOT.TB test for patients with indeterminate results on the QuantiFERON TB-2G test. Intern Med. 2009; 48(3): 137-142.
44. Park SY, Jeon K, Um SW, Kwon OJ, Kang ES, KohWJ. Clinical utility of the QuantiFERON-TB Gold In-Tube test for the diagnosis of active pulmonary tuberculosis. Scand J Infect Dis. 2009; 41(11-12): 818-822.
45. Dilektasli AG, Erdem E, Durukan E, Eyoglu FO. Is the T-cell-based interferon-gamma releasing assay feasible for diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country? Jpn J Infect Dis. 2010; 63(6): 433-436.
46. Boyd AE, Ashcroft A, Lipman M, Bothamley GH. Limited added value of T-SPOT.TB blood test in diagnosing active TB: A prospective Bayesian analysis. J Infect. 2011; 62(6): 456-461.
47. Cho OH, Park KH, Kim SM, et al. Diagnostic performance of T-SPOT.TB for extrapulmonary tuberculosis according to the site of infection. J Infect. 2011; 63(5): 362-369.
48. Kim EY, Park MS, Kim YS, Kim SK, Chang J, Kang YA. Risk factors for false-negative results of QuantiFERON-TB Gold In-Tube assay in non-HIV-infected patients with culture-confirmed tuberculosis. Diagn Microbiol Infect Dis. 2011; 70(3): 324-329.
49. Lai CC, Tan CK, Lin SH, et al. Diagnostic value of an enzyme-linked immunospot assay for interferon-γ in cutaneous tuberculosis. Diagn Microbiol Infect Dis. 2011; 70(1): 60-64.
50. Lai CC, Tan CK, Lin SH, Liao CH, Huang YT, Hsueh PR. Diagnostic performance of whole-blood interferon-γ assay and enzyme-linked immunospot assay for active tuberculosis. Diagn Microbiol Infect Dis. 2011; 71(2): 139-143.
51. Lui G, Lee N, Cheung SW, et al. Interferon gamma release assay for differentiating tuberculosis among pneumonia cases in acute healthcare setting. J Infect. 2011; 62(6): 440-447.
52. Ra SW, Lyu J, Choi CM, et al. Distinguishing tuberculosis from Mycobacterium avium complex disease using an interferon-gamma release assay. Int J Tuberc Lung Dis. 2011; 15(5): 635-640.
53. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, OkaM. Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. Intern Med. 2012; 51(10): 1199-1205.
54. Lee J, Lee SY,Won DI, Cha SI, Park JY, Kim CH. Comparison of whole-blood interferon-γ assay and flow cytometry for the detection of tuberculosis infection. J Infect. 2013; 66(4): 338-345.
55. Taki-Eddin L, Monem F. Utility of an interferon-gamma release assay as a potential diagnostic aid for active pulmonary tuberculosis. J Infect Dev Ctries. 2012; 6(1): 67-72.
56. Feng JY, Huang SF, Lee MC, et al. Characteristics of IFN-γ responses in IGRA among pulmonary TB suspects in a TB-endemic area. Diagn Microbiol Infect Dis. 2013; 77(1): 46-52.
57. Jeon YL, Nam YS, You E, et al. Factors influencing discordant results of the QuantiFERON-TB Gold In-Tube test in patients with active TB. J Infect. 2013; 67(4): 288-293.
58. Kim S, Kim YK, Lee H, et al. Interferon gamma mRNA quantitative real-Time polymerase chain reaction for the diagnosis of latent tuberculosis: A novel interferon gamma release assay. Diagn Microbiol Infect Dis. 2013; 75(1): 68-72.
59. Min JW, Lee HY, Lee JS, et al. Effect of prolonged incubation time on results of the QuantiFERON TB Gold In-Tube assay for diagnosis of latent tuberculosis infection. Clin Vaccine Immunol. 2013; 20(9): 1377-1380.
60. Lee YJ, Lee J, Kim YY, et al. Performance of whole-blood interferon-gamma release assay in patients admitted to the emergency department with pulmonary infiltrates. BMC Infect Dis. 2011; 11: 107.
61. Wlodarczyk M, RudnickaW, Janiszewska-Drobinska B, et al. Interferon-gamma assay in combination with tuberculin skin test are insufficient for the diagnosis of culture-negative pulmonary tuberculosis. PLoS One. 2014; 9(9): E107208.
62. Kim CH, Lim JK, Yoo SS, et al. Diagnostic performance of the QuantiFERON-TB Gold In-Tube assay and factors associated with nonpositive results in patients with miliary tuberculosis. Clin Infect Dis. 2014; 58(7): 986-989.
63. Seibert AF, Haynes J Jr, Middleton R, Bass JB Jr. Tuberculous pleural effusion: Twenty-year experience. Chest. 1991; 99(4): 883-886.
64. Fietta A, Meloni F, Cascina A, et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control. 2003; 31(6): 347-353.
65. Berkel GM, Cobelens FG, de Vries G, Draayer-Jansen IW, BorgdorffMW. Tuberculin skin test: Estimation of positive and negative predictive values from routine data. Int J Tuberc Lung Dis. 2005; 9(3): 310-316.
66. Goletti D, Carrara S, Vincenti D, et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: A pilot study. Clin Microbiol Infect. 2006; 12 (6): 544-550.
67. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2007; 44(1): 69-73.
68. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Quantitative scoring of an interferon-gamma assay for differentiating active from latent tuberculosis. Eur Respir J. 2007; 30(4): 722-728.
69. Losi M, Bossink A, Codecasa L, et al; European Tuberculosis Network TBNET. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J. 2007; 30(6): 1173-1179.
70. Mazurek GH,Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis. 2007; 45(7): 837-845.
71. Bocchino M, Chairadonna P, Matarese A, et al. Limited usefulness of QuantiFERON-TB Gold In-Tube for monitoring anti-Tuberculosis therapy. Respir Med. 2010; 104(10): 1551-1556.
72. Metcalfe JZ, Cattamanchi A, Vittinghoff E, et al. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med. 2010; 181(1): 87-93.
73. Ruhwald M, Dominguez J, Latorre I, et al; TBNET. A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis. Tuberculosis (Edinb). 2011; 91(3): 260-267.
74. Walsh MC, Camerlin AJ, Miles R, et al. The sensitivity of interferon-gamma release assays is not compromised in tuberculosis patients with diabetes. Int J Tuberc Lung Dis. 2011; 15(2): 179-184.
75. Erdem H, Ozturk-Engin D, Elaldi N, et al. The microbiological diagnosis of tuberculous meningitis: Results of Haydarpasa-1 study. Clin Microbiol Infect. 2014; 20(10): O600-O608.
76. Katsenos S, Nikolopoulou M, Konstantinidis AK, et al. Interferon-gamma release assay clarifies the effect of bacille Calmette-Gu?in vaccination in Greek army recruits. Int J Tuberc Lung Dis. 2010; 14 (5): 545-550.
77. Mazurek GH, Zajdowicz MJ, Hankinson AL, et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis. 2007; 45(7): 826-836.
78. Bienek DR, Chang CK. Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis. Int J Tuberc Lung Dis. 2009; 13(11): 1416-1421.
79. Bellete B, Coberly J, Barnes GL, et al. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis. 2002; 34(11): 1449-1456.
80. Mancuso JD, Mazurek GH, Tribble D, et al. Discordance among commercially available diagnostics for latent tuberculosis infection. Am J Respir Crit Care Med. 2012; 185(4): 427-434.
81. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA. 2001; 286(14): 1740-1747.
82. Taggart EW, Hill HR, Ruegner RG, Martins TB, Litwin CM. Evaluation of an in vitro assay for gamma interferon production in response to Mycobacterium tuberculosis infections. Clin Diagn Lab Immunol. 2004; 11(6): 1089-1093.
83. Taggart EW, Hill HR, Ruegner RG, Litwin CM. Evaluation of an in vitro assay for interferon gamma production in response to the Mycobacterium tuberculosis-synthesized peptide antigens ESAT-6 and CFP-10 and the PPD skin test. Am J Clin Pathol. 2006; 125(3): 467-473.
84. Villarino ME, BurmanW,Wang YC, et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. JAMA. 1999; 281(2): 169-171.
85. Villarino ME, Brennan MJ, Nolan CM, et al. Comparison testing of current (PPD-S1) and proposed (PPD-S2) reference tuberculin standards. AmJ Respir Crit Care Med. 2000; 161(4, pt 1): 1167-1171.
86. Bua A, Molicotti P, Delogu G, et al. QuantiFERON TB Gold: A new method for latent tuberculosis infection. New Microbiol. 2007; 30(4): 477-480.
87. Lempp JM, Margan JZ, Hankinson AL, Toney S, Keep LW, Mazurek G. Assessment of the QuantiFERON-TB Gold In-Tube Test for the Detection of Mycobacterium tuberculosis Infection in US Navy Recruits. Atlanta, GA: Centers for Disease Control and Prevention; 2015.
88. Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: A preliminary report. J Gastroenterol Hepatol. 2001; 16(9): 1028-1032.
89. Dorman SE, Belknap R, Graviss EA, et al; Tuberculosis Epidemiologic Studies Consortium. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med. 2014; 189(1): 77-87.
90. Franken WP, Thijsen S,Wolterbeek R, et al. Variation in T-SPOT.TB spot interpretation between independent observers from different laboratories. Clin Vaccine Immunol. 2009; 16(10): 1439-1442.
91. WhitworthWC, Hamilton LR, Goodwin DJ, et al. Within-subject interlaboratory variability of QuantiFERON-TB gold in-Tube tests. PLoS One. 2012; 7(9): E43790.
92. WhitworthWC, Goodwin DJ, Racster L, et al. Variability of the QuantiFERON?-TB Gold In-Tube test using automated and manual methods. PLoS One. 2014; 9(1): E86721.
93. O'Shea MK, Fletcher TE, Beeching NJ, et al. Tuberculin skin testing and treatment modulates interferon-gamma release assay results for latent tuberculosis in migrants. PLoS One. 2014; 9(5): E97366.
94. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004; 170(4): 445-449.
95. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: A randomized trial. Ann Intern Med. 2008; 149(10): 689-697.
96. Sterling TR, Villarino ME, Borisov AS, et al; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23): 2155-2166.
97. Thompson MJ; International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial. BullWorld Health Organ. 1982; 60(4): 555-564.
98. White MC, Tulsky JP, Lee JR, et al. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: Toxicity and adherence. J Correct Health Care. 2012; 18(2): 131-142.
99. Rker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneitymay mislead. BMC Med ResMethodol. 2008; 8: 79.
100. Li SJ, Jiang H, Yang H, et al. The dilemma of heterogeneity tests in meta-Analysis: A challenge from a simulation study. PLoS One. 2015; 10(5): E0127538.
101. Menzies D, Pai M, Comstock G. Meta-Analysis: New tests for the diagnosis of latent tuberculosis infection: Areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146(5): 340-354.
102. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med. 2008; 149(3): 177-184.
103. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: Ametaanalysis. Chest. 2010; 137(4): 952-968.
104. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: A systematic review and meta-Analysis. Eur Respir J. 2011; 37(1): 88-99.
105. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000; (2): CD001363.
106. US Preventive Services Task Force. Section 3: TopicWork Plan Development in US Preventive Services Task Force Procedure Manual. http://www.uspreventiveservicestaskforce.org/Page/Name/methods-And-processes. 2016. Accessed June 6, 2016.